Matrix-assisted laser desorption/ionization mass spectra reflect solution-phase zinc finger peptide complexation  by Lehmann Renato Zenobi, Edda & Vetter, Stefan
Matrix-Assisted Laser Desorption/Ionization
Mass Spectra Reflect Solution-Phase Zinc
Finger Peptide Complexation
Edda Lehmann and Renato Zenobi
Laboratory of Organic Chemistry, ETH Zu¨rich, Zu¨rich, Switzerland
Stefan Vetter
Laboratory of Biochemistry, ETH Zu¨rich, Zu¨rich, Switzerland
The complexation between an 18-residue zinc finger peptide of CCHC type (CCHC 5
Cys-X2-Cys-X4-His-X4-Cys, X 5 variable amino acid) from the gag protein p55 of human
immunodeficiency virus type 1 (HIV-1) and various transition metal ions was studied by
means of circular dichroism spectroscopy and matrix-assisted laser desorption/ionization
mass spectrometry (MALDI-MS). A correlation between the complexation behavior in solution
and in MALDI-MS could be established. It was shown that MALDI-MS is a fast method
suitable for studying metal binding properties of zinc finger complexes. (J Am Soc Mass
Spectrom 1999, 10, 27–34) © 1999 American Society for Mass Spectrometry
Matrix-assisted laser desorption/ionizationmass spectrometry (MALDI-MS) is a power-ful tool for the analysis of various biomol-
ecules and synthetic polymers [1–3]. When studying
biological systems with MALDI-MS, it is very impor-
tant to know whether a correspondence between liquid
phase behavior and the observed gas-phase ions exists,
for example, whether “preformed” ions present in the
liquid phase are detected in the mass spectrum. This is
especially important for noncovalently bound com-
plexes and complexes of biomolecules with metal ions.
These are stable under physiological conditions, but
may not survive laser desorption and ionization pro-
cesses. Up to now, only very little has been done with
MALDI [4, 5], and with electrospray ionization (ESI)
mass spectrometry [6–8] to compare solution and gas
phase chemistries of noncovalent and metal ion–bi-
omolecule complexes. An important issue is also to
distinguish between specific and nonspecific aggrega-
tion, which may happen in the MALDI plume [9, 10].
Hutchens et al. [11, 12] evaluated the metal binding
properties of a histidine-rich peptide. These authors
report the capability of MALDI-MS to determine the
peptide–metal binding capacity which agreed with the
results from direct titration in solution. The absence of
Mn21– and Co21– but presence of Cu21–peptide com-
plex signals in MALDI spectra also demonstrated that
specific metal ion–peptide interactions can be detected
with MALDI-MS. Further evidence for the ability of
MALDI-MS to probe solution phase binding was given
by Nelson et al. [5] who worked with the same histi-
dine-rich peptide. After washing a sample containing
matrix, peptide, and metal salt, copper–peptide adducts
were still observed in the MALDI spectra, whereas
sodium and potassium adducts disappeared. This ob-
servation was attributed to the fact that the copper
adducts already exist in solution, but not the sodium
and potassium adducts.
To our knowledge, the only MALDI study on the
complexation between zinc finger peptides and metal
ions has been published by Woods et al. [13]. Two
experiments with a zinc finger peptide of Cys2-His2
type have been performed. In one of them, the authors
varied the peptide:Zn21 molar ratio. Molar ratios
smaller than or equal to 1:1 yielded similar spectra,
whereas an excess of peptide resulted in a decrease of
the Zn21–peptide complex signal. In another experi-
ment, Co21 was used instead of Zn21. In contrast to the
Zn21 complex, the Co21–peptide complex was barely
visible in the MALDI spectra. This was explained by a
difference of four orders of magnitude between the
dissociation constants of both complexes. However, it is
known that conclusions drawn from absolute intensities
are problematic in MALDI mass spectrometry. The
success in obtaining these MALDI spectra of metal
ion–zinc finger peptide complexes was attributed to the
sample solutions’ neutral pH which preserved the pep-
tide’s folded structure.
The purpose of this study was to establish a correla-
tion between the complexation of a zinc finger peptide
and transition metal ions in solution and in MALDI
mass spectrometry. Various factors affecting metal ion–
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zinc finger peptide binding in solution, e.g., the transi-
tion metal ions used, the molar ratio of peptide and
metal ion, and the pH were investigated.
The peptide selected for the investigation is an
18-residue peptide with an amino acid sequence com-
prising the first zinc finger domain from the gag protein
p55 of human immunodeficiency virus type 1 (HIV-1),
called p55F1, which has never been studied with
MALDI before. The zinc binding domain corresponds
to the motif CCHC (CCHC 5 Cys-X2-Cys-X4-His-X4-
Cys, X 5 variable amino acid) present in retroviral
nucleocapsid proteins. The peptide has no defined
secondary structure in the absence of metal ions. Metal
ion binding induces peptide folding which is required
for the interaction with nucleic acids [14, 15]. CCHC
type peptides bind Zn21 very tightly, whereas the
complexes with other transition metal ions are weaker
[16, 17]. The three-dimensional structure of the Zn21
complex of p55F1 has first been solved by Summers et
al. [18]. Zn21 is tetrahedrally coordinated by three
cysteine and one histidine residue. As individual zinc
finger domains are small (a few kDa) and behave as
almost complete independent units, they are syntheti-
cally accessible and are ideal model systems for entire
nucleocapsid proteins [19]. For most experiments,
6-aza-2-thiothymine (ATT) was used as a MALDI ma-
trix for the analysis of p55F1 and the metal ion–p55F1
complexes. This basic matrix was recently shown to be
suited for the detection of noncovalent compounds [20,
21]. Solutions were studied by means of circular dichro-
ism (CD) spectroscopy, whereas gas-phase behavior
was studied using MALDI-MS. Circular dichroism
spectroscopy is suited to investigate the structure of the
peptide and therefore of the peptide–metal ion com-
plex, because the secondary structure elements present
(b-sheet, b-turn, or random coil) show characteristic CD
spectra [22]. The metal ion specificity of p55F1 was
evaluated using Zn21, Cd21, Co21, and Ni21. A molar
excess of the metal ion compared to p55F1 had to be
used to detect a strong MALDI signal of the metal
ion–p55F1 complex, whereas an equimolar amount of
metal ion and peptide was sufficient to completely form




The zinc finger peptide was synthesized in our labora-
tory (see below). Zinc(II) chloride (ZnCl2), cobalt(II)
chloride hexahydrate (CoCl2 z 6H2O), nickel(II) chloride
hexahydrate (NiCl2 z 6H2O), ethylene-diamine tetraace-
tic acid disodium salt dihydrate (EDTA), 2,5-dihy-
droxybenzoic acid (DHB), and trifluoroacetic acid
(TFA) were purchased from Fluka Chemie AG (Buchs,
Switzerland). Diammonium hydrogen citrate, ammo-
nium bicarbonate (NH4HCO3), and 6-aza-2-thiothym-
ine (ATT) were obtained from Aldrich Chemie (Buchs,
Switzerland). Cadmium(II) chloride dihydrate (CdCl2 z
2H2O) and copper(II) chloride dihydrate (CuCl2 z
2H2O) were purchased from Siegfried Handel (Zofin-
gen, Switzerland). Tris(hydroxymethyl)aminoethane
(Tris), and gramicidin S were aquired from Sigma
Chemie (Buchs, Switzerland). The VS-dialysis mem-
brane (0.025 mm) was obtained from Millipore
(Volketswil, Switzerland). The TentaGel S resin was
purchased from Rapp Polymere (Tu¨bingen, Germany).
Fmoc amino acids were obtained from Novabiochem
(La¨ufelfingen, Switzerland). All materials obtained
from commercial sources were used without further
treatment or purification. Aqueous solutions were pre-
pared using distilled water.
Peptide Synthesis and Purification
The zinc finger peptide p55F1 has the sequence
acVKCFNCGKEGHIARNCRA-OH. A second peptide
was also used for the experiment involving the varia-
tion of the molar ratio of peptide and Zn21. It differs
from p55F1 only by substitution of isoleucin by valine
at position 12 (p55F1m). Judging from CD spectroscopy,
the modification had no effect on the metal binding
behavior. The peptides were acetylated at the N-termi-
nal end and therefore have molecular weights of 2049
and 2034 g/mol, respectively. They were synthesized
manually on TentaGel S resin using Fmoc-protected
amino acid derivatives. The peptides were purified on a
reversed phase-high performance liquid chromatogra-
phy (RP-HPLC) C18 column.
Oxidation Behavior of the Peptide
The thiol groups of the CCHC motif’s three cysteine
residues are oxidation sensitive. The HPLC purified
peptide was stored after lyophilization under an argon
or nitrogen atmosphere at room temperature. No sig-
nificant oxidation was observed during storage. When
dissolved in degassed water at pH 7.5 and stored in a
closed Eppendorf tube, less than 15% of the peptide was
oxidized within 4 h (followed by using Ellman’s reagent
and VIS absorption spectroscopy at 412 nm [23]). Be-
cause we always worked with solutions that were
freshly prepared or younger than 2 h for MALDI and
CD sample preparation, it is justified to not protect
them from air. For the investigation of the metal ion
specificity of p55F1, it was also important to know
whether metal ion addition induces more extensive
peptide oxidation, as transition metal ion–thiolate com-
plexes are potentially oxidation sensitive. Within 1.5 h,
all metal ions studied (1.5 molar equivalents added to
peptide) did not lead to any significant oxidation. As a
control, we used Cu21, which we found in similar
experiments to be much more effective in oxidizing the
peptide. Using again a 50% molar excess, Cu21 lead to
70% oxidation of the peptide, most probably accompa-
nied by reduction of Cu(II) to Cu(I).
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Mass Spectrometry
MALDI time-of-flight (TOF) experiments were per-
formed on a home-built 2 m linear TOF mass spectrom-
eter. The total acceleration voltage was 125 kV. Desorp-
tion was performed using a nitrogen laser (model
VSL-337ND-T, Laser Science, MA), incident at ;60° of
the surface normal. The laser was attenuated by two
glass plates and an adjustable iris. The energy after
attenuation was measured with a pyroelectric detector
(model ED 100, Gentec, Quebec, Canada). Laser pulse
energies were generally in the range of 20 to 40 mJ.
Typically, spectra were obtained by averaging 100 sin-
gle shots in order to enhance the signal-to-noise ratio of
the mass spectra. All the mass spectra shown were
recorded in positive ion mode. A more detailed descrip-
tion of the setup can be found in the paper of Dubois et
al. [24]. Where mass-to-charge ratio values are noted in
the text, average masses are given.
For one test experiment, a mass resolution exceeding
the one of our TOF instrument was needed. For this
purpose, the spectrum was recorded on a Fourier
transform ion cyclotron resonance (FTICR) mass spec-
trometer, consisting of a 4.7 tesla superconducting mag-
net, a cylindrical cell (Bruker, Fa¨llanden, Switzerland)
and a workstation-based data acquisition system (Od-
yssey, Finnigan/Extrel FTMS, Madison, WI). The sam-
ple was irradiated with 355 nm from a frequency-
tripled Nd:YAG laser (Continuum, Model Surelite II, 5
ns pulse width). The working pressure was below 1 3
1028 mbar. The mass resolution was .10,000 in the
FTICR experiment.
MALDI Sample Preparation
Generally, an aqueous ATT (35 mM, pH 4–5) matrix
solution was used for MALDI sample preparation. In
order to vary the solution pH, ATT was dissolved in
aqueous Tris (10 mM), NH4HCO3 (20 mM) or 0.1% TFA
in water to yield pH values of 7.5, 7, and 1.5, respec-
tively. For one experiment, an aqueous DHB (100 mM,
pH 2) matrix solution was used. Equal volumes of
aqueous zinc finger peptide (0.1 mM), matrix, and
aqueous metal chloride solutions (0.3 to 10 mM) were
mixed to yield the molar ratios indicated in the figure
legends. 2–4 mL of the resulting solution were depos-
ited on the probe tip, partially dried in a cool air stream,
and then completely dried in the vacuum. For the zinc
complexation experiment with EDTA, the aqueous li-
gand solution (2.2 mM) was first desalinated using the
Millipore “drop dialysis method” [25, 26]. 10 mL of the
solution were placed on a VS membrane, which was
then allowed to float on a 100 mM solution of diammo-
nium hydrogen citrate. After ;15 min, the sample was
removed from the membrane. For analysis, an aliquot
of this solution was added to a solution containing the
peptide, matrix, and ZnCl2 in order to yield the molar
ratios indicated in the figure legend.
Circular Dichroism Spectroscopy
Measurements were performed on a Jasco J-600 spec-
tropolarimeter. The temperature (22–23°C) was con-
trolled using a water-jacketed cuvette holder and an
external water bath. Spectra were recorded between 190
and 280 nm in a 0.1 mm pathway cuvette. The spectra
were averaged over three scans. The peptide was nor-
mally dissolved in 50 mM Tris buffer pH 7.5 (1 mM).
Concentrations of metal salts in 50 mM Tris buffer pH
7.5 were chosen in order to obtain the final solution by
a 1:1 mixing (volume) with the peptide solution.
Results and Discussion
Figure 1 depicts the MALDI mass spectra of p55F1 with
ATT as a matrix. The spectrum in Figure 1A of the
apo-peptide is dominated by the protonated molecular
ion peak, [M1H]1 (m/z 2050). Minor signals corre-
spond to the sodiated molecular ion, and impurities at
masses M148 and M 2 43, the latter possibly represent-
ing the nonacetylated peptide. Upon addition of 10
molar equivalents of Zn21 (Figure 1B), a signal corre-
Figure 1. MALDI mass spectra with ATT matrix of (A) peptide
p55F1 alone, (B) peptide and Zn21 in molar ratio 1:10, and (C)
peptide and Zn21 in molar ratio 1:10 with addition of gramicidin
S. Solvent: water. The final solution has a pH value of 5. The
spectra were normalized to the [M1H]1 signal. The inset in (B) is
a schematic view of the Zn21–p55F1 complex.
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sponding to the peptide adduct with Zn21, [M 2
H1Zn]1 (m/z 2114), appears. This composition has
been confirmed by FTICR mass spectrometry: the dif-
ference between the monoisotopic masses of the pro-
tonated peptide and the zinc–peptide adduct equals
62.0, corresponding to the monoisotopic mass of (Zn–
2H). This observation also agrees with the results of
Wong et al. [27] as well as Woods et al. [13]. To be more
precise, [M 2 H1Zn]1 can be written as [M 2
2H1Zn1H]1 in order to account for the fact that p55F1
loses two thiol protons upon Zn21 complexation, and
aquires an additional proton to form a singly charged
species [28]. The spectra in Figure 1 and in the other
figures of this work were normalized to the [M1H]1
signal. In the following, the ratio of the intensities (peak
integrals) of the [M 2 2H1Zn1H]1 signal to the
[M1H]1 signal is called relative intensity of [M 2
2H1Zn1H]1. The [M 2 2H1Zn1H]1 signal can either
represent a specific 1:1 complex or a nonspecific adduct.
To check this, the peptide gramicidin S, which does not
form specific adducts with Zn21, has been added to the
peptide and Zn21 containing solution (Figure 1C). The
relative intensity of [M 2 2H1Zn1H]1 is the same as
without addition of gramicidin S. The Zn21 adduct of
gramicidin S, [G 2 H1Zn]1, is negligible. This experi-
ment indicates a specific 1:1 complex of Zn21 with
peptide p55F1. Clearly it is important to know whether
this specific complex is formed in the condensed phase
or in the gas phase after desorption.
The association reaction of Zn21–p55F1 in solution
can be written as
p55F11Zn21º [(p55F1)1Zn]21 (1)
Equilibria similar to eq 1 exist for metal centers other
than Zn21, but unfortunately, complex formation con-
stants with p55F1 are not available from the literature.
They are assumed to be similar to those reported for a
CCHC sequence in murine leukemia virus, i.e., 1010
M21 for the Zn21, and between 105 and 5 3 107 M21 for
the Co21 complex [16, 17]. Cd21 has the same valence
electronic configuration as Zn21 but a larger ionic
radius. Krizek et al. [29] indicate a similar formation
constant for the Cd21 and the Zn21 complex with a zinc
finger peptide containing the sequence Cys-X2-Cys-X12-
His-X3-Cys. It is not known whether these data are also
valid for the p55F1 peptide, because the effect of a
change in the chain length between the cysteine and
histidine residues and of a different amino acid se-
quence cannot easily be estimated. For these reasons,
the affinity of p55F1 for different metal ions was inves-
tigated using CD spectroscopy and MALDI-MS. Figure
2 shows the CD spectra of p55F1 alone and in the
presence of various metal ions. The spectrum of apo-
p55F1 (Figure 2D) is typical for an unstructured peptide
(random coil). It is characterized by a negative mini-
mum at 198 nm. Addition of various metal ions induces
significant changes of the spectrum. A nuclear magnetic
resonance study of the Zn21–complexed peptide re-
vealed a b-turn as dominant secondary structural ele-
ment and a short b-sheet [18]. b-Turns are reported to
show a positive CD band between 205 and 220 nm [30].
Indeed a positive band with a maximum at 212 nm is
found in the Zn21–p55F1 complex besides a 5 nm red
shift of the negative minimum (Figure 2A). However,
CD active charge transfer bands appear between 200
and 230 nm in spectra of Zn21-containing metallothio-
neins [31]. It is difficult to attribute the band at 212 nm
either to the b-turn or to the charge transfer effect and
therefore no unambiguous conformational analysis
based on these CD spectra was possible.
The CD region between 190 and 200 nm was chosen
to investigate the metal–peptide interaction. This region
is not affected by CD bands related to metal peptide
charge-transfer effects. Because complexation induces
folding, the CD spectra give a qualitative estimate of the
formation constants of the different metal ion–p55F1
complexes. In terms of binding hierarchy, the formation
constants with p55F1 decrease in the series from Zn21
over Cd21/Co21 to Ni21. The CD spectrum of Co21–
p55F1 was about the same as the one of the Cd21
complex (data not shown).
If MALDI spectra reflect solution behavior, then
these differences should be reflected in the relative
intensities of the metal ion–peptide complex signals.
Figure 3 shows MALDI spectra of the corresponding
samples. The relative intensities of the metal ion–pep-
tide signals are smaller for Cd21 (m/z 2161) and Ni21
(m/z 2107) than for Zn21. Relative signal intensities for
the Ni21 and Cd21 complexes as well as for the Co21
complex (not depicted) are roughly the same. MALDI
spectra therefore clearly suggest a high affinity for Zn21
and a lower affinity for Cd21, Ni21, and Co21. This was
observed using both the basic matrix ATT, and the
Figure 2. CD spectra of p55F1 alone and with different metal
ions in molar ratio 1:5. Solvent: 20 mM aqueous Tris, pH 5 7.4.
The binding constants of the metal ion–p55F1 complexes decrease
from (A) to (D).
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acidic matrix DHB. In summary, these experiments
indicate a correlation between the behavior of the metal
ion–peptide complexes in solution and for the gas
phase. Furthermore, they show that in contrast to the
above-mentioned zinc finger sequence Cys-X2-Cys-X12-
His-X3-Cys, the sequence Cys-X2-Cys-X4-His-X4-Cys in
p55F1 has a lower affinity for Cd21 than for Zn21. As a
corrolary, our results also support the discrimination
between Zn21 and Co21 by the same CCHC zinc finger
motif in the murine leukemia virus [16, 17].
It should be emphasized that, in the present study, a
correlation between the behavior of the metal ion–
peptide complex in solution and in the gas phase is said
to exist if changes in solution conditions lead to corre-
sponding changes in the MALDI spectra. Absolute
complex abundances in solution and complex peak
intensities in the MALDI spectra can, of course, not be
directly compared.
The formation constant for the Zn21–EDTA complex
in solution is 1016 M21 [32]. It is several orders of
magnitude larger than the formation constant of the
Zn21–p55F1 complex. Addition of EDTA to a solution
containing this Zn21–p55F1 complex is expected to shift
eq 1 to the left side since Zn21 is eliminated from the
equilibrium through complexation with EDTA. This
was confirmed by CD spectroscopy. The spectrum of a
solution of p55F1 and Zn21 (Figure 2A) which shows an
ordered structure of the peptide changed its appearance
to that of the unfolded peptide as shown in Figure 2D
when a slight molar excess of EDTA compared to Zn21
was added. The corresponding MALDI spectra are
depicted in Figure 4. It can clearly be seen that the [M 2
H1Zn]1 signal in Figure 4A disappears when EDTA is
added (Figure 4B). The obtained spectrum looks like the
one of the peptide alone (Figure 1A). These results
reveal a reversible complex formation between Zn21
and p55F1 which can be followed both by CD spectros-
copy and MALDI-MS.
We next investigated the effect on the MALDI spec-
tra of an increase of the molar ratio of Zn21 to p55F1 in
solution. According to eq 1, an increase of the amount of
complexes formed in solution is expected because the
equilibrium is shifted to the right. CD spectroscopy
confirmed this observation. Spectra were taken at dif-
ferent molar ratios of Zn21 to peptide. Figure 5 shows
the relative signal intensity in the CD spectra at 212 nm
as a function of the molar ratio. The intensity rises up to
a molar ratio of about 1:1 and then reaches saturation.
The same is observed when taking the relative signal
intensity at 198 nm. This agrees with observations from
Frankel et al. [33]. The behavior reflects an increase of
the peptide’s ordered structure with the molar ratio of
Zn21 to peptide, i.e., an increasing amount of com-
Figure 3. MALDI mass spectra of p55F1 alone and with different
metal ions in molar ratio 1:10. Matrix: ATT. Solvent: water. The
final solution has a pH of 5. The relative signal intensity of the
metal ion–peptide complex in (B) and (C) is smaller than in (A).
The [M 2 2H 1 Zn 1 H]1 signal in (C) is broader than the other
metal ion–peptide complex signals because the Ni21 complex
signal overlaps with the impurity signal at [M148[1. The spectra
were normalized to the [M 1 H]1 signal.
Figure 4. MALDI mass spectrum of (A) p55F1 and Zn21 in molar
ratio 1:10, and (B) p55F1, Zn21, and EDTA in molar ratio 1:10:12.
Solvent: water. Matrix: ATT. The final solution has a pH value of
5. The [M 2 2H1Zn1H]1 signal disappears upon EDTA addi-
tion. The spectra were normalized to the [M1H]1 signal.
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plexed peptide. Figure 6 shows the MALDI spectra of
p55F1m at different molar ratios with Zn21 using DHB
as a matrix. An increase of the relative intensity of the
[M 2 2H 1 Zn 1 H]1 signal with the molar ratio of
Zn21 to peptide is clearly visible. This result correlates
with the result from CD spectroscopy.
We have seen that in solution a molar ratio of Zn21
to peptide of 1:1 is sufficient to completely form the
Zn21–peptide complex, whereas a large excess of Zn21
is needed to see a significant [M 2 2H 1 Zn 1 H]1
signal besides the [M 1 H]1 signal in MALDI spectra.
The observation can possibly be explained as follows.
First, the desorption, ionization, and detection efficien-
cies of [M1H]1 and [M 2 2H 1 Zn 1 H]1 are differ-
ent. The same amount of both the peptide and the
Zn21–peptide complex in solution can probably lead to
a peptide MALDI signal that is much more intense than
the complex signal. Second, the pH of the solution for
the MALDI experiments was lower than the one for the
CD experiments, resulting in a decrease of the relative
intensity of the [M 2 2H 1 Zn 1 H]1 signal (see pH
study below). Third, it is possible that a certain amount
of the complex ions present in the solid phase dissoci-
ates during the MALDI process. Fourth, partial oxida-
tion of the peptide during MALDI sample preparation
may adversely affect the complexation. As CD spectros-
copy and MALDI mass spectrometry rely on com-
pletely different principles, the results can therefore not
be compared quantitatively, but only qualitatively. This
is sufficient to establish a correlation between the be-
havior of a species in solution, probed by CD spectros-
copy, and in the gas phase, probed by MALDI-MS.
A further MALDI experiment revealed that besides
the ions formed in the condensed phase prior to desorp-
tion, some are also formed by gas-phase reactions after
desorption. A solid mixture of peptide in DHB was
thoroughly mixed in different molar ratios with a solid
mixture of ZnCl2 in DHB. All components were dried
before use and manipulated in a glove box in order to
prevent dissolution on the particles’ surface and thus
complex formation prior to the MALDI experiment. The
MALDI spectra showed a [M 2 2H 1 Zn 1 H]1 sig-
nal, whose relative intensity increased with the molar
ratio of Zn21 to peptide.
In order to account for the pH dependence of the
complexation of p55F1 and Zn21 in solution, which is
not included in eq 1, a modified complexation equilib-
rium must be considered. At neutral pH, the basic side
Figure 5. Titration of p55F1 with Zn21. The signal intensity in
presence of zinc(II) relative to the signal intensity of the unfolded
peptide in the CD spectra at 212 nm is depicted as a function of the
molar ratio of Zn21 to peptide. It rises up to a molar ratio of about
1:1 and then reaches saturation. Solvent: 50 mM aqueous Tris,
pH 5 7.5.
Figure 6. MALDI mass spectra of p55F1m and Zn21 at different
molar ratios. Solvent: water. Matrix: DHB. The final solution has a
pH value of 2.5. The relative intensity of [M 2 2H1Zn1H]1
increases with the molar ratio of Zn21 to peptide. The signal at
2200 Da [marked with a question mark in spectrum (D)] could not
be identified. The spectra were normalized to the [M 1 H]1
signal.
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chains of the two arginine and the two lysine residues
of p55F1 are protonated, and glutamic acid, as well as
the terminal carboxylic acid group are deprotonated.
This results in an overall doubly protonated peptide.
Upon formation of the tetrahedral metal ion–zinc finger
peptide complex, at least two of the three cysteine–SH
groups are deprotonated [28]:
@~p55F1) 1 2H]21 1 Zn21º [(p55F1) 1 Zn]21 1 2H1
(2)
According to eq 2, addition of base leads to an increase
of the amount of metal ion–peptide complexes. Above
pH 6, CD spectra of solutions of peptide and Zn21 in
molar ratio 1:1 in the presence of ATT matrix reveal an
ordered peptide structure similar to the one seen in the
CD spectrum in Figure 2A, which disappears at lower
pH values. This means that the complex between p55F1
and Zn21 is not stable at a pH , 6. Figure 7 shows
MALDI spectra of p55F1 in the presence of Zn21 ions at
various pH values of the sample solutions. ATT could
successfully be used as a matrix at different pH values,
which was not possible for an acidic matrix such as
DHB. The relative intensity of the [M 2 2H1Zn1H]1
signal increases with pH. In the MALDI spectrum of the
solution buffered with Tris to pH 7.5, peptide adducts
with two Zn21 ions, with ATT, as well as with Zn21 and
ATT are also detected besides sodium and potassium
adducts. Binding of the second Zn21 ion is assumed to
be nonspecific because the zinc finger motif exclusively
complexes to one Zn21 ion. A further experiment with
NH4HCO3 to adjust the pH yielded the same MALDI
spectrum as with the Tris buffer. Obviously, Tris, which
is not lyophilizable as is NH4HCO3, does not deterio-
rate the MALDI spectra. This confirms the salt tolerance
of this method [34]. The study on the pH dependence of
the complexation between peptide and Zn21 demon-
strated that MALDI results reflect solution behavior.
For the size of peptide used in the study, singly charged
species are commonly observed in MALDI mass spec-
tra. In the MALDI plume, the charge state of the species
in solution is balanced by protonation or deprotonation.
Note that the MALDI spectra at a pH below 6 exhibit
Zn21–peptide complex signals, whereas CD spectra of
the solutions at this pH do not. This is most probably
because of the fact that MALDI spectra are taken from
crystalline samples. We have shown in previous work
that the amount of complexes present in the solid phase
is higher than in solution if volatile byproducts, such as
HCl, form upon complexation [7]. The reason for this is
the elimination of the acid with the solvent during
crystallization, which results in a shift of equilibrium 2
to the right side.
Conclusions
We investigated various factors affecting the interaction
between the zinc finger peptide p55F1 and metal ions
by means of CD spectroscopy of the solution and
MALDI-MS of the gas phase. The most important
results are:
• A correlation exists between the behavior of the metal
ion–p55F1 complex in solution and in MALDI spec-
tra. Both CD spectroscopy and MALDI-MS reveal a
specific and reversible interaction between p55F1 and
Zn21 ions, and allow the qualitative evaluation of the
affinity of p55F1 for different metal ions.
• Ions formed prior to desorption (“preformed ions”)
are shown to be important in MALDI-MS of coordi-
nation compounds of biochemical relevance.
• MALDI-MS is a fast tool suitable for studying metal
binding properties of zinc finger peptides.
As an outlook, MALDI-MS may also serve as a power-
ful method for testing other noncovalent compounds,
such as complexes between zinc finger peptides and
Figure 7. MALDI mass spectra of p55F1 and Zn21 in molar ratio
1:10 at various pH. Solvent: water. Matrix: ATT. TFA and Tris
were used to adjust the different pH values. The relative intensity
of [M 2 2H1Zn1H]1 increases with the pH from 0.4 at pH 1.5
over 0.9 at pH 5 to 1.4 at pH 7.5. The spectrum at pH 7.5 shows
more sodium and potassium adducts than the other spectra. This
is because of the sodium and potassium salt impurities of Tris. The
sodium and potassium adducts of the peptide and those of the
Zn21–peptide complex have been considered as belonging to
[M1H]1 and [M 2 2H1Zn1H]1, respectively, when calculating
the relative intensity of the Zn21–peptide signal. The spectra were
normalized to the [M1H]1 signal.
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oligonucleotides, that are known to play a role in gene
regulation.
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